TILS-021 Study for Secondary Progressive MS

The aim of this study is to prevent the immune system's attack and to dampen inflammation in the brain. The study is testing the investigational medication Foralumab, which is given as a nasal inhalation 3 times per week.

Participants will be randomly selected to receive placebo or the study drug; each participant has a 2 out of 3 chances of getting the active medication. Neither you nor your doctor will know which treatment you received. The study will include study drug, blood testing, MRIs and PET scans. The total duration of the study will be approximately 3-5 months.

To find out more or to volunteer for this trial, write to MSResearch@yale.edu or katerina.palma@yale.edu and reference the "Tiziana trial".